Latest Headlines

Latest Headlines

GlySure gets CE mark for first continuous intravascular glucose monitor for hospital use

Managing blood glucose levels tightly helps improve morbidity and mortality rates among diabetics. That's particularly true for diabetics who have other major health problems. Now British startup GlySure has gained a CE mark specifically for use in intensive care units with adult cardiac surgery patients. Until now, blood glucose management for these critically ill patients often required frequent manual monitoring by the hospital staff.

Actelion creates €30M vax startup, Immunocore expands Lilly deal, Cell Therapy seeks PhIII ally

In this week's EuroBiotech Report, Actelion bet €30 million ($33 million) on the potential of synthetic carbohydrate vaccines, becoming the majority shareholder in a biotech created to develop assets discovered at the Max Planck Society and giving it exposure to the vaccine field without interfering with its core business. And more.

Pharma Two B mulls IPO after posting PhIIb Parkinson's data

Pharma Two B has stepped up its hunt for financing after its Parkinson's disease combination drug came through a Phase IIb trial. The data have given Pharma Two B the confidence to start talking up a possible IPO or partnership deal as it moves toward gathering the cash needed for a pivotal study.

Immunocore lands immuno-oncology combination trial deal with Lilly

Immunocore has added another string to its collaboration with Eli Lilly. The deal is intended to show whether there is value in combining Immunocore's lead T cell receptor-based therapy with galunisertib and merestinib in patients with metastatic cutaneous and uveal melanomas.

Cell Therapy weighs up partnership options after regenerative medicine aces PhII

Cell Therapy has posted positive data from a Phase II trial of its topical regenerative medicine to repair severe tendon injury. And with mid-stage data in the bag and a sizable potential market awaiting commercialization of the product, the regenerative medicine specialist is now assessing its partnership options.

Biogen to build $1B plant, add 400 jobs in Switzerland

Biogen has looked at its pipeline of promising drug candidates for things like Alzheimer's disease and multiple sclerosis, measured that against its manufacturing network and decided it is going to need more capacity. The company announced on Tuesday that it will start with a $1 billion plant in Switzerland, where it expects to add 400 jobs.

Actelion creates vaccine startup with €30M investment and Max Planck assets

Actelion has got into startup creation. The Swiss biotech has committed €30 million ($33 million) to set up Vaxxilon, a synthetic carbohydrate vaccine-focused startup with a mission to push a program licensed from the Max Planck Society into the clinic within the next three years.

Adocia climbs 10% after Lilly-partnered insulin clears PhIb

Shares in Adocia rose 10% after its Eli Lilly-partnered fast-acting insulin impressed in a small early-phase study. The data position Adocia to push ahead with development of a product that could surpass Lilly's blockbuster fast-acting insulin Humalog in terms of speed and effectiveness.

Alexion gets EU green light for a pair of rare disease drugs

European regulators are recommending approval for two rare disease treatments from Alexion, a victory for the biotech as it works to expand its stable of commercialized drugs.

Google backs £320M Oxford fund, DBV heads to Phase III, Biophytis files for Paris IPO

In this week's EuroBiotech Report, two corners of Britain's great hope for competing with the likes of Boston and San Francisco, the area dubbed the "golden triangle," spent the week talking about the one area in which they indisputably fall short of their rivals: Cash. And more.